Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AmberGen, Inc. maintains a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This action is assigned to 1 distinct examiner and 1 distinct art unit. This distribution signifies a concentrated effort in a single technical domain for the company's current filings.
The busiest examiner for this portfolio is PUTTLITZ, KARL J. This examiner is responsible for 1 pending office action. Because the total count of pending actions is 1, PUTTLITZ, KARL J manages the entirety of the company's active prosecution workload. No other examiners are currently reviewing pending matters for this entity.
The involvement of 1 distinct art unit indicates that the pending technology is classified within a specific group. Practitioners can focus their prosecution strategy on the standards of that art unit and the specific tendencies of PUTTLITZ, KARL J. This centralized structure for the 1 pending office action allows for a direct relationship with the assigned examiner in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmberGen, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karl J Puttlitz has the most, with 1 of AmberGen, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
